Idexx Laboratories Total Liabilities increased by 4.8% to $1.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.6%, from $1.77B to $1.83B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows relatively stable performance with a 1.0% CAGR.
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
total_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.66B | $1.63B | $1.75B | $1.95B | $2.15B | $2.16B | $2.14B | $1.97B | $1.78B | $1.79B | $1.78B | $1.78B | $1.83B | $1.73B | $1.70B | $1.77B | $1.87B | $1.83B | $1.75B | $1.83B |
| QoQ Change | — | -2.0% | +7.2% | +11.8% | +10.1% | +0.6% | -1.2% | -8.0% | -9.7% | +0.7% | -0.8% | +0.5% | +2.8% | -5.6% | -2.0% | +4.0% | +6.0% | -2.5% | -4.4% | +4.8% |
| YoY Change | — | — | — | — | +29.2% | +32.7% | +22.4% | +0.7% | -17.4% | -17.3% | -17.0% | -9.3% | +3.2% | -3.1% | -4.4% | -1.1% | +2.0% | +5.4% | +2.8% | +3.6% |